[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-337320-105":59,"doc-detail-337320-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","co-delivery-of-liposomal-ketoconazole-and-bevacizumab-for-synergistical-inhibition-of-angiogenesis-against-endometrial-cancer","Co-delivery of Liposomal Ketoconazole and Bevacizumab for Synergistical Inhibition of Angiogenesis Against Endometrial Cancer","","Study designs a liposome-based co-delivery formulation to transport a cancer-derived exosome inhibitor (ketoconazole, Keto) together with an angiogenesis inhibitor (bevacizumab, mAb). The Combo-Lipo formulation is characterized by a uniform ~100 nm particle size and strong serum and long-term physical stability. Cell viability assays show reduced cancer-cell viability versus free drugs, with liposomes suppressing angiogenic mediators and tumor immune suppressive factors. The formulation also downregulates angiogenic factor production, inhibits tumor-associated macrophages, and reduces tumor-promoting factor expression for endometrial cancer therapy.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/co-delivery-of-liposomal-ketoconazole-and-bevacizumab-for-synergistical-inhibition-of-angiogenesis-against-endometrial-cancer/337320/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/co-delivery-of-liposomal-ketoconazole-and-bevacizumab-for-synergistical-inhibition-of-angiogenesis-against-endometrial-cancer/337320.png","ImageObject",300,407,{"name":92,"@type":93},"Ophelia","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-16","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the Combo-Lipo formulation designed to deliver?","Question",{"text":112,"@type":113},"It co-delivers a cancer-derived exosome inhibitor (ketoconazole, Keto) and an angiogenesis inhibitor (bevacizumab, mAb) using a liposome-based approach.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does the Combo-Lipo formulation perform in characterization and stability?",{"text":117,"@type":113},"It shows a uniform average particle size of about 100 nm and excellent serum and long-term physical stability.",{"name":119,"@type":110,"acceptedAnswer":120},"What anti-tumor mechanisms are reported for Combo-Lipo in endometrial cancer?",{"text":121,"@type":113},"Combo-Lipo reduces cancer-cell viability, downregulates angiogenic factors and related mediators, and inhibits tumor-associated macrophages (TAMs), lowering tumor-promoting factor expression.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},337320,1790498438,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},7971461741311,"https://ap-avatar.wpscdn.com/avatar/74000253aff267980c6?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779345379180704826","Molecular Biotechnology (2025) 67:2660–2672  \n[https://doi.org/10.1007/s12033-024-01227-1](https://doi.org/10.1007/s12033-024-01227-1)  \nCo‑delivery of Liposomal Ketoconazole and Bevacizumab for Synergistical Inhibition ofAngiogenesis Against Endometrial Cancer  \nShanshan Wang1 · Jinglin Miao2 · Ping Zhu3 · Li Xu2  \nReceived: 8 September 2023 / Accepted: 20 June 2024 / Published online: 4 September 2024 © The Author(s) 2024  \nAbstract  \nIn this study, we designed a novel formulation based on liposomes for the co-delivery of cancer-derived exosome inhibitor (ketoconazole, Keto) and angiogenesis inhibitor (bevacizumab, mAb) . The designed Combo-Lipo formulation was systematically characterized, exhibiting a uniform average particle size of 100 nm, as well as excellent serum and long-term physical stabilities. The cell viability assay revealed that Combo-Lipo treatment significantly reduced the viability of cancer cells compared to free drugs. Moreover, liposomes effectively inhibited angiogenic mediators and reduced tumor immune suppressive factors. The Combo-Lipo formulation demonstrated potent downregulation of angiogenic factors and synergistic effects in suppressing their production. Furthermore, liposomes inhibited tumor-associated macrophages (TAMs), leading to decreased expression of tumor-promoting factors. Together, these findings highlighted the promising characteristics of Combo-Lipo as a therapeutic formulation, including optimal particle size, serum stability, and potent anti-cancer effects, as well as inhibition of angiogenic mediators and TAMs toward treating endometrial cancer.  \nKeywords Endometrial cancer · Liposomes · Co-delivery · Cancer-associated fibroblasts · Tumor-associated macrophages  \nIntroduction  \nEndometrial cancer has emerged as one of the harmful cancers characterized by the significant challenges of often being diagnosed at an advanced stage, resulting in significant mortality rates among women [1] . In this context, cancer-derived exosomes play significant roles in promoting  \nShanshan Wang and Jinglin Miao have equal contribution in this paper.  \n* Ping Zhu [zhuzp111@126.com](zhuzp111@126.com)  \n* Li Xu [xuli10011@163.com](xuli10011@163.com)  \n1 Department of the First Obstetrics and Gynecology, Yantai Yuhuangding Hospital, Yantai 264099, Shandong, China  \n2 Department of the Third Obstetrics and Gynecology, Yantai Yuhuangding Hospital, No. 20 Yuhuangding East Road, Zhifu District, Yantai 264099, Shandong, China  \n3 Department of Reproductive Medicine, Yantai Yuhuangding Hospital, No. 20 Yuhuangding East Road, Zhifu District, Yantai 264099, Shandong, China  \nand progressing various tumors [2] . Due to various bioactive molecules, such as proteins, lipids, and nucleic acids, exosomes can influence the behavior of recipient cells. Accordingly, cancer-derived exosomes act as agents for intercellular communication and promote tumor growth by enhancing cell proliferation, angiogenesis (neovascularization process to substantial tumor growth), and metastasis (spreading cancer cells to distant sites) [3, 4] . In addition, exosomes modulate the tumor microenvironment (TME) by suppressing the immune system and promoting inflammation. These attributes in the tumor can create a favorable microenvironment for tumor survival and expansion [5] . In this context, a report demonstrated that cancer-derived exosomes could be implicated in drug resistance, as they could transfer drug efflux pumps and signaling molecules to recipient cells, thereby reducing the therapeutic efficacy of anti-cancer treatments [6] . Furthermore, cancer-derived exosomes facilitate the formation of pre-metastatic niches, altering the behavior of stromal cells, such as fibroblasts, endothelial cells, and immune cells, in the target organ [7] . The exosomes released from primary tumor cells convert the macrophage in the tumor site to tumor-associated  \nmacrophages (TAMs), an important contributor to metastasis in the development of endom","cbCaiaDqGNx6UQ6a","https://ap.wps.com/l/cbCaiaDqGNx6UQ6a","pdf",4478055,13,"English","# Abstract\n# Keywords\n# Introduction","[{\"question\":\"What is the Combo-Lipo formulation designed to deliver?\",\"answer\":\"It co-delivers a cancer-derived exosome inhibitor (ketoconazole, Keto) and an angiogenesis inhibitor (bevacizumab, mAb) using a liposome-based approach.\"},{\"question\":\"How does the Combo-Lipo formulation perform in characterization and stability?\",\"answer\":\"It shows a uniform average particle size of about 100 nm and excellent serum and long-term physical stability.\"},{\"question\":\"What anti-tumor mechanisms are reported for Combo-Lipo in endometrial cancer?\",\"answer\":\"Combo-Lipo reduces cancer-cell viability, downregulates angiogenic factors and related mediators, and inhibits tumor-associated macrophages (TAMs), lowering tumor-promoting factor expression.\"}]","Co-delivery of Liposomal Ketoconazole and Bevacizumab for Synergistical Inhibition of Angiogenesis Against Endometrial Cancer | PDF",1790018582,33,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b343d289588775b7added1a35d569bfd.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/33d5407e3c5ace0d67709eb59386f792.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/769c9a73e315fb0f585ce7671788a1f6.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/462fd8e32a640e298449f71581fd5fb8.webp",980,1301]